Twice Daily Prevacid for the Treatment of Laryngopharyngeal Reflux
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether treatment with twice-daily Lansoprazole
30mg (Prevacid 30mg) and behavioral modifications for reflux is superior to treatment with
behavioral modifications for reflux alone in the treatment of laryngopharyngeal reflux (LPR).